Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced today the pricing of an underwritten public
offering of 10 million shares of newly issued common stock at a price to the
public of $8.40 per share, before underwriting discounts and commissions.
Exelixis expects the net proceeds from the offering to be approximately
$78.7 million. Exelixis intends to use the net proceeds to fund the continued
clinical development of its product candidates as well as for working capital
and general corporate purposes.
Goldman, Sachs & Co. is acting as the sole book-running manager for the
offering. Cowen and Company, LLC is acting as the joint lead manager, and Banc
of America Securities LLC and Piper Jaffray & Co. are acting as co-managers
for the offering. Exelixis also granted the underwriters a 30-day option to
purchase up to an additional 1.5 million shares of common stock. All of the
shares in the offering are being sold by Exelixis.
A registration statement relating to these securities has been filed with
and declared effective by the Securities and Exchange Commission. The offering
may be made only by means of a prospectus supplement and the accompanying
prospectus. Copies of the final prospectus supplement and the accompanying
prospectus may be obtained by sending a request to Goldman, Sachs & Co., Attn:
Prospectus Department, 85 Broad Street, New York, New York 10004, Fax:
212-902-9316 or Email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, any of the securities, nor shall there be any
sale of these securities, in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state.
Exelixis, Inc. is a biotechnology company dedicated to the discovery and
development of novel therapeutics that will potentially enhance the care and
lives of patients with cancer and other serious diseases.
SOURCE Exelixis, Inc.
CONTACT: Frank Karbe, Chief Financial Officer, +1-650-837-7565, or
email@example.com, or Charles Butler, Director, Corporate Communications,
+1-650-837-7277, or firstname.lastname@example.org, both of Exelixis, Inc.
Web site: http://www.exelixis.com/